Clinical Observation Of Huxinkang Tablet In The Treatment Of Stable Angina Pectoris And Syndrome Of Coronary Heart Disease

Objective: To observe and evaluate the associate curative effect and safety of the Huxinkang tablet on the stable angina pectoris(SAP)with the syndrome of phlegm and blood stasis(PBS).Methods: On the basis of random number table method,60 inpatients of SAP with the syndrome of PBS in the Affiliated Hospital of the Hunan Academy of Chinese Medicine were selected and randomly divided into the treatment group(30 cases)and control group(30 cases).The patients in the control group were administered with the basic western medicine treatment. And the patients in the treatment group were treated with the Huxinkang tablet plus the basic western medicine treatment. The treatment course was four weeks. The clinical effect and curative effect of the angina pectoris(AP),electrocardiograph(ECG)and Chinese medicine syndrome(CMS)are observed after the treatment, as well as the change of indices of the blood fat, Duke score and SAQ score before and after the treatment.Results:(1)Both the treatment group and control group can improve the clinical curative effect, and the total effective rate of the clinical curative effect was 90.0% in treatment group but 76.7% in the control group. There was a significant difference between the two groups(P<0.05);(2)Both the treatment group and control group can improve the ECG curative effect,and the total effective rate of the ECG curative effect was 80.0% in treatment group but 63.3% in the control group. There was a significant difference between the two groups(P<0.05);(3)Both the treatment group and control group can improve the AP curative effect,and the total effective rate of the AP curative effect was 86.7% in treatment group but 66.7% in the control group. There was a significant difference between the two groups(P<0.05);(4)Both the treatment group and control group can improve the glonoine reduction,and the total effective rate of the glonoine reduction was 90.0% in treatment group but 76.7% in the control group. There was a significant difference between the two groups(P<0.05);(5)Both the treatment group and control group can improve the CMS curative effect,and the total effective rate of the CMS curative effect was 90.0% in treatment group but 73.3% in the control group. There was a significant difference between the two groups(P<0.05);(6)The blood fat are improved in both two groups, and there were significant differences before and after the treatment in both two groups(P<0.05). Besides, these indices of the treatment group are superior to those of the control group, and there was a significant difference between the two groups(P<0.05);(7)There were significant differences before and after the treatment in Duke score and SAQ score in both two group(P<0.05). Moreover, these indices of the treatment group are superior to those of the control group, and there was a significant difference between the two groups(P<0.05);(8)There was no obvious change of the dectetion of the blood, electrolyte, and liver and kidney function in both two groups, as well as no serious adverse reaction, and there was no statistical signification in and between two groups(P>0.05), thus the routine therapy associate with the Huxinkang tablet also has good security.Conlusion: There was a significant advantage of associate with the Huxinkang tablet in treatment of the SAP patients with the syndrome of PBS, which can improve lipid metabolism function, the Duke score of angina pectoris of patients with SAP in treadmill exercise test, and the quality of life of patients with SAP.